Economic evaluation of combination treatment of Zepatier (Elbasvir/Grazoprevir) and Ribavirin for Hepatitis C Virus (Genotype 1, 4, 5, 6) in Norway
The main question is: “Is the Zepatier-based treatment is more cost-effective that
interferon-based treatment?”. There is still no evaluation of QALY, ICER of new treatment.
The study will include the quantitative and comparative analysis.
My plan is to make an economic analysis including cost-effectiveness analysis that will demonstrate the comparison of incremental costs with incremental benefits for health.
The data sources will include the expert opinion, literature review, hopefully results of medical trials.
TSD
- Ja
Biobank
- Nei
Godkjenninger
NSD - Ikke behov
Prosjektet er basert på allerede publiserte data og er derfor ikke søknadspliktig.
REK - Ikke behov
Prosjektet er basert på allerede publiserte data og er derfor ikke søknadspliktig.